Is IDRA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

154 people get IDRA articles and Market Currents by email alert.

Get email alerts on IDRA »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

There are no Focus articles on IDRA.

To learn more about Seeking Alpha Pro, click here.

3 Biotech Stocks To Consider In The Wake Of Recent Developments
Matt Schilling • Wed, Dec 19, 2012 • 2 Comments
4 Reasons Why Merck Could Be The Perfect Stock For Dividend Investors
Trade In Mexico • Fri, Nov 30, 2012
Medical Advances May Help Improve Psoriasis Outcomes
Michael Becker • Sun, Nov 11, 2012 • 3 Comments
2012 Preview: Cancer Immunotherapy Catalysts
Michael Becker • Thu, Dec 15, 2011 • 20 Comments
6 Cheap Biotech Stocks With Big Upside Potential
Rougemont • Tue, Oct 25, 2011 • 7 Comments
Adjuvants May Hold Key To Unlocking Cancer Immunotherapy Revolution
Michael Becker • Tue, Sep 20, 2011 • 12 Comments
5 Companies Providing Clinical Trial Updates This Week
Alex Shadunsky • Fri, Jul 8, 2011 • 1 Comment
15 Biotech Stocks With the Lowest Put/Call Ratios
Kapitall • Wed, Oct 13, 2010 • 3 Comments
Two IPOs Brave the Markets, Two Enter the Queue: Biotech's Latest Deals
The Burrill Report • Sun, Aug 8, 2010 • 1 Comment
Volume Talks Wednesday: A Bullish Biotech Breakout Option Play
Option Maestro • Thu, Mar 25, 2010
Biotech Stocks for a Possible Year-End Rally
R. Scott Raynovich • Wed, Nov 18, 2009 • 2 Comments
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Justin M. Hall • Sun, Sep 20, 2009 • 18 Comments
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
Justin M. Hall • Fri, Sep 11, 2009 • 33 Comments
Cancer Stocks Finish a Tough Quarter
Alan Brochstein • Mon, Oct 1, 2007
Cancer Stocks: The Bleeding Slows
Alan Brochstein • Mon, Jul 2, 2007
Cancer Stocks Hammered Once Again
Alan Brochstein • Tue, Jun 26, 2007 • 7 Comments
Cancer Stocks Slide Again
Alan Brochstein • Mon, Jun 18, 2007 • 1 Comment
Cancer Stocks Plunge Following ASCO Meeting
Alan Brochstein • Mon, Jun 11, 2007 • 3 Comments
Cancer Stocks Soar With Annual ASCO Meeting
Alan Brochstein • Mon, Jun 4, 2007 • 1 Comment
Cancer Stocks on the Go: Winners and Losers
Alan Brochstein • Tue, May 29, 2007 • 3 Comments

There are no Transcripts on IDRA.

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis

Business Wire (Jun 5, 2013)
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results

Business Wire (May 15, 2013)
Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis

Business Wire (May 8, 2013)
Idera Pharmaceuticals Announces Closing of Common Share Offering

Business Wire (May 7, 2013)
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants

Business Wire (May 1, 2013)
Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program

Business Wire (Apr 1, 2013)
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease Program

Business Wire (Mar 11, 2013)
Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis Model

Business Wire (Mar 2, 2013)
Idera Pharmaceuticals Announces Presentation at American Academy of Dermatology Annual Meeting

Business Wire (Feb 26, 2013)
Idera to Present at the 15th Annual BIO CEO and Investor Conference

Business Wire (Feb 5, 2013)
Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to-Severe Plaque Psoriasis

Business Wire (Dec 19, 2012)
Idera to Present at the Piper Jaffray Healthcare Conference

Business Wire (Nov 26, 2012)
Idera Announces Initiation of Lupus Clinical Development Program with Phase 1 Trial of IMO-8400

Business Wire (Nov 13, 2012)
Idera Pharmaceuticals Reports Third Quarter 2012 Financial Results

Business Wire (Nov 12, 2012)
Idera Pharmaceuticals Completes $7.0 Million Financing

Business Wire (Nov 12, 2012)
Idera Pharmaceuticals Present New Data That Show Toll-like Receptor Antagonists Inhibit Inflammasome Activation and Suppress Induction of Interleukin 1 Beta in Autoimmune Disease Models

Business Wire (Oct 30, 2012)
Idera Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients with Psoriasis

Business Wire (Oct 15, 2012)
Idera Pharmaceuticals to Present at the 3rd Annual Cancer Immunotherapy Conference

Business Wire (Sep 28, 2012)
Idera Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

Business Wire (Aug 31, 2012)
Idera Pharmaceuticals Reports Second Quarter 2012 Financial Results

Business Wire (Aug 9, 2012)

IDRA vs. ETF Alternatives

Company Description

Currently, there's no company description for IDRA.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 1:36 PM Idera Pharmaceuticals (IDRA -1.9%) slips today, despite reporting a slightly better Q1. The company posted a loss of $0.15 per share, compared to a loss of $0.25 per share in the same period last year. Revenues were $7K, down from $9K in the prior-year period. Analysts had expected the company to record no revenues for the quarter. Comment! [Healthcare, Earnings, On the Move]
Monday, April 1, 2:13 PM Idera Pharmaceuticals (IDRA +3.5%) moves up today after announcing earlier that it's completed dosing in Phase 1 trials of IMO-8400, currently in clinical development for the treatment of autoimmune diseases. In addition, the company says that its protocol for a Phase 2 study in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. Comment! [Healthcare, On the Move]
Wednesday, December 19, 2012, 11:02 AM Idera Pharmaceuticals (IDRA +25.8%) ramps higher out of the gate after saying that its lead drug candidate IMO-3100, a treatment for moderate-to-severe plaque psoriasis, was more effective than a placebo in a Phase IIa clinical trial of two dose levels. The company thinks the trial data for the injectable treatment provides clinical proof-of-concept for the mechanism that suppresses certain factors that underlie the skin disorder. Comment! [Healthcare, On the Move]
Thursday, July 21, 2011, 8:46 AM Idera Pharmaceuticals (IDRA) says the FDA has told it to freeze a planned midstage trial to test its IMO-3100 candidate for the treatment of psoriasis. The company hasn't yet received a written notice, which will detail the FDA's reasoning behind the halt. Shares -1.5% premarket. Comment! [Healthcare, On the Move]

IDRA Idera Pharmaceuticals, Inc.

IDRA

Idera Pharmaceuticals, Inc.